A study from the University of California, Los Angeles; California Institute of Technology, Pasadena; Medical Research Council; and National Institute for Medical Research, London has reported that “Transcriptomics identified a critical role for Th2 cell-intrinsic miR-155 in mediating allergy and antihelminth immunity.”
This study was published in the July 14, 2014 Proc Natl Acad Sci U S A [I.F >10] by The 1975 Nobel prize winner for Physiology/Medicine, Prof. David Baltimore and others from the University of California, Los Angeles; California Institute of Technology, Pasadena; and Medical Research Council, National Institute for Medical Research, London.
On the foundation of this interesting finding, Dr L Boominathan, Director-cum-chief Scientist of GBMD, reports here that: Insights into the treatment of Th2-mediated inflammation and allergic diseases: 17α-E2 (an estrogen derivative) alleviates Th2-medited inflammation and Allergy via up regulation of its target gene. This study suggests that 17α-E2, by increasing the expression of its target gene, it could alleviate antihelminthimmunity. Together, this study suggests that pharmacological formulations encompassing “17α-E2 (an estrogen derivative) or its analogues” can be used to treat inflammation and allergic diseases.
Idea Proposed/Formulated by: Dr L Boominathan PhD
Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/
Courtesy: When you cite drop us a line at info@genomediscovery.org
Citation: Boominathan, L., Insights into the treatment of Th2-mediated inflammation and allergic diseases: 17α-E2 (an estrogen derivative) alleviates Th2-medited inflammation and Allergy via up regulation of its target gene., 06/October/2014, 10.10 am, Genome-2-Bio-Medicine Discovery center (GBMD), http://genomediscovery.org
Web: http://genomediscovery.org
*Research cooperation